Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis
- PMID: 10563530
- DOI: 10.1097/00042737-199911000-00006
Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis
Abstract
Objective: To assess the long-term effect of the addition of long-acting nitrates to beta-blockers on liver blood flow and liver metabolic activity in patients with cirrhosis and portal hypertension.
Methods: Eleven patients with cirrhosis and portal hypertension were investigated by using hepatic vein catheterization and indocyanine green (ICG) constant infusion on baseline conditions, after 1 month of treatment with nadolol, after 3 months of treatment with nadolol plus isosorbide mononitrate, and (in seven cases) after 1 year of combined treatment.
Results: The hepatic venous pressure gradient decreased significantly after nadolol, and more so after addition of isosorbide mononitrate. Hepatic blood flow, and ICG intrinsic hepatic clearance did not change significantly, although few cases showed an increase or decrease in either parameter. A significant correlation was found between changes in ICG intrinsic hepatic clearance and in hepatic venous pressure gradient (r = 0.62, P = 0.04).
Conclusions: Liver blood flow and liver metabolic activity are not consistently affected by addition of isosorbide mononitrate to nadolol. Substantial decreases in portal pressure may be associated with a decrease in ICG intrinsic hepatic clearance.
Similar articles
-
Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment.J Hepatol. 1998 Apr;28(4):622-30. doi: 10.1016/s0168-8278(98)80286-9. J Hepatol. 1998. PMID: 9566831 Clinical Trial.
-
Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.Hepatology. 1997 Jul;26(1):34-9. doi: 10.1053/jhep.1997.v26.pm0009214449. Hepatology. 1997. PMID: 9214449 Clinical Trial.
-
Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.Ann Intern Med. 1991 May 15;114(10):869-73. doi: 10.7326/0003-4819-114-10-869. Ann Intern Med. 1991. PMID: 2014947 Clinical Trial.
-
Complications of cirrhosis. I. Portal hypertension.J Hepatol. 2000;32(1 Suppl):141-56. doi: 10.1016/s0168-8278(00)80422-5. J Hepatol. 2000. PMID: 10728801 Review.
-
Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.Drugs. 1999 Feb;57(2):261-77. doi: 10.2165/00003495-199957020-00016. Drugs. 1999. PMID: 10188765 Review.
Cited by
-
Comparison of portal hypertensive gastropathy and gastric antral vascular ectasia: an update.Gastroenterol Hepatol Bed Bench. 2022 Summer;15(3):204-218. doi: 10.22037/ghfbb.v15i3.2561. Gastroenterol Hepatol Bed Bench. 2022. PMID: 36311963 Free PMC article. Review.
-
Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.World J Gastroenterol. 2020 Oct 28;26(40):6111-6140. doi: 10.3748/wjg.v26.i40.6111. World J Gastroenterol. 2020. PMID: 33177789 Free PMC article. Review.
-
Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?Dig Dis Sci. 2002 Dec;47(12):2669-73. doi: 10.1023/a:1021088618300. Dig Dis Sci. 2002. PMID: 12498283
-
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.Int J Mol Sci. 2020 Aug 28;21(17):6223. doi: 10.3390/ijms21176223. Int J Mol Sci. 2020. PMID: 32872119 Free PMC article. Review.
-
Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.Dig Dis Sci. 2002 Feb;47(2):401-4. doi: 10.1023/a:1013790610327. Dig Dis Sci. 2002. PMID: 11855558
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical